(2024, October 15). Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024: Three abstracts accepted for poster presentations on ALG-000184 and ALG-055009. NASDAQ OMX's News Release Distribution Channel.
Chicago Style (17th ed.) Citation"Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024: Three Abstracts Accepted for Poster Presentations on ALG-000184 and ALG-055009." NASDAQ OMX's News Release Distribution Channel 15 Oct. 2024.
MLA (9th ed.) Citation"Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024: Three Abstracts Accepted for Poster Presentations on ALG-000184 and ALG-055009." NASDAQ OMX's News Release Distribution Channel, 15 Oct. 2024.